Two antiviral drugs are available in Australia, but one is prescribed more routinely. Here’s what you need to know as we navigate the eighth COVID wave.
Academic rigor, journalistic flair
Articles on Molnupiravir
Displaying all articles
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.
Just as access to vaccines was vastly more difficult for low-income countries, the same is now true for the virus’ treatments: at potentially great cost to the world.
The drug has been authorised for the use in the UK and elsewhere, but some are calling for further testing.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Merck announced preliminary data suggesting the drug reduced the risk of hospitalisation and death by 50%.
Top contributors
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Senior Technical Advisor - HIV, The Nossal Institute for Global Health, PhD candidate La Trobe University, The University of Melbourne
-
Associate Professor and Chief Health Officer - COVID and Health Emergencies, Burnet Institute
-
Professor of Cancer Virology, University of Leeds
-
Adjunct Clinical Professor, Monash University
-
Associate Professor in Public Health, La Trobe University
-
Postdoctoral Research Fellow, RNA Biology and Biochemistry, Brighton and Sussex Medical School
-
Associate Professor in Pharmacology, University of Sydney
-
PhD candidate at The Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
Pharmacist and PhD Candidate, University of Sydney
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
